There’s a new cell-based cancer immunotherapy on the block.

A flurry of induced pluripotent stem cell banks are coming online, but they face significant business challenges.

There are benefits of studying certain biological processes under microgravity, but whether those advantages outweigh the costs of getting experiments off Earth remains to be seen.

The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

A fraught market for the barbiturates prescribed to terminally ill patients who choose to end their lives has physicians turning to options outside big pharma.

The state’s industry draws inspiration from medicine as well as agriculture.

Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.

Jamie Heywood, chief executive of the Amyotrophic Lateral Sclerosis Therapy Development Foundation (ALSTDF), founded the nonprofit biotech company in 1999 after his brother was diagnosed with ALS.

J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard

From a mass photometer to improved breath biopsy probes, these new products are poised for scientific success.